

Pressure BioSciences, Inc.

10:35 04 Jun 2020

Pressure BioSciences eyeing around \$2.4 million in 1Q 2021 as it sells its first manufacturing run of BaroShear K45 systems

Pressure BioSciences Inc (OTCQB:PBIO) revealed that its initial manufacturing run of 12 of its BaroShear K45 processing systems had now sold out, with the final one being bought by a licensed Massachusetts hemp processor Canopy CBD Farms.

The system is based on the the Massachusetts-based Pressure Bio's proprietary ultra shear technology (UST) platform and is designed to solve a critical problem for the hemp-derived cannabinoid industry, namely, how to make the cannabinoid oil soluble in water.

READ: According to Forbes, Pressure noted, the US cannabidiol market is projected to exceed \$20 billion by 2024.

According to Forbes, Pressure noted, the US cannabidiol market is projected to exceed \$20 billion by 2024.

The firm had aimed to complete the 12 systems during the fourth quarter of 2020 but due to inefficiencies caused by the coronavirus pandemic, it now reckons they will be ready for shipment and installation to occur during the first quarter of 2021.

"Much progress has been made in the development of this very novel and innovative nanoemulsification processing system," said Richard T. Schumacher, president and CEO of Pressure Biosciences in a statement.

"We have finished the development of and run many processing cycles with the test bed. Our team is now beginning development of the BaroShear K45 alpha (first) unit. We expect to complete this unit by the end of September 2020 so it will be available for testing by the companies who placed the initial 12 orders.

"Upon their approval, we expect to ship and install all 12 BaroShear K45 systems during Q1 2021, at which point we will recognize approximately \$2.4 million in revenue. This is a very exciting milestone event for all shareholders in Pressure BioSciences."

John Westlake, founder and president of Canopy CBD Farms, added: "After an exhaustive review of available technologies, a thorough evaluation of UST-processed hemp-derived cannabinoid materials, and a detailed and encompassing site visit, we concluded the BaroShear K45 was unmatched in the universe of nanoemulsion processing platforms."


Canopy CBD farms serves pharmaceutical and medical research companies, wishing to establish white label/co-branded manufacturing partnerships with cGMP, GLP manufacturers.

It says its partnerships will increase wholesale and retail distribution channels, with a ready to label line of high quality, salable hemp-derived CBD products, for a variety of uses and industries.

Price: 1.46

Market Cap: \$5.67 m

1 Year Share Price Graph



December 2019 June 2020 November 20

Share Information

Code: PBIO

Listing: OTCQB

52 week	High	Low
	4.49	0.6006

Sector: Medical technology & services

Website: www.pressurebiosciences.com

Company Synopsis:

Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.

action@proactiveinvestors.com

Contact the author at giles@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).